Official reprint from UpToDate®
www.uptodate.com ©2018 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Acute cystitis: Management and prognosis in children older than two years and adolescents

Debra L Palazzi, MD, MEd
Judith R Campbell, MD
Section Editors
Tej K Mattoo, MD, DCH, FRCP
Sheldon L Kaplan, MD
Deputy Editor
Mary M Torchia, MD


Cystitis is inflammation of the urinary bladder, usually caused by infection, which can occur alone or in conjunction with pyelonephritis.

The management and prognosis of acute cystitis in children older than two years and adolescents will be reviewed here. The clinical features and diagnosis of acute cystitis in children older than two years and adolescents is discussed separately. (See "Acute cystitis: Clinical features and diagnosis in children older than two years and adolescents".)

Urinary tract infection in newborns and children younger than two years (in whom it is difficult to distinguish cystitis from pyelonephritis on clinical grounds) also is discussed separately.

(See "Urinary tract infections in neonates".)

(See "Urinary tract infections in children: Epidemiology and risk factors".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Dec 2017. | This topic last updated: Jan 04, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2018 UpToDate, Inc.
  1. Shaikh N, Morone NE, Lopez J, et al. Does this child have a urinary tract infection? JAMA 2007; 298:2895.
  2. National Institute for Health and Care Excellence. CG54 Urinary tract infection in children. 2007. http://guidance.nice.org.uk/CG54/Guidance/pdf/English (Accessed on March 03, 2014).
  3. Boggan JC, Navar-Boggan AM, Jhaveri R. Pediatric-specific antimicrobial susceptibility data and empiric antibiotic selection. Pediatrics 2012; 130:e615.
  4. Fitzgerald A, Mori R, Lakhanpaul M, Tullus K. Antibiotics for treating lower urinary tract infection in children. Cochrane Database Syst Rev 2012; :CD006857.
  5. Gaspari RJ, Dickson E, Karlowsky J, Doern G. Antibiotic resistance trends in paediatric uropathogens. Int J Antimicrob Agents 2005; 26:267.
  6. Prais D, Straussberg R, Avitzur Y, et al. Bacterial susceptibility to oral antibiotics in community acquired urinary tract infection. Arch Dis Child 2003; 88:215.
  7. Ladhani S, Gransden W. Increasing antibiotic resistance among urinary tract isolates. Arch Dis Child 2003; 88:444.
  8. Mehr SS, Powell CV, Curtis N. Cephalosporin resistant urinary tract infections in young children. J Paediatr Child Health 2004; 40:48.
  9. Bryce A, Hay AD, Lane IF, et al. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ 2016; 352:i939.
  10. Shaikh N, Hoberman A, Keren R, et al. Predictors of Antimicrobial Resistance among Pathogens Causing Urinary Tract Infection in Children. J Pediatr 2016; 171:116.
  11. Karlowsky JA, Jones ME, Thornsberry C, et al. Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999. Int J Antimicrob Agents 2001; 18:121.
  12. US Food and Drug Administration. FDA Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm (Accessed on May 13, 2016).
  13. United States Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm (Accessed on July 28, 2016).
  14. Jackson MA, Schutze GE, COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics 2016; 138.
  15. Tran D, Muchant DG, Aronoff SC. Short-course versus conventional length antimicrobial therapy for uncomplicated lower urinary tract infections in children: a meta-analysis of 1279 patients. J Pediatr 2001; 139:93.
  16. Keren R, Chan E. A meta-analysis of randomized, controlled trials comparing short- and long-course antibiotic therapy for urinary tract infections in children. Pediatrics 2002; 109:E70.
  17. Michael M, Hodson EM, Craig JC, et al. Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children. Cochrane Database Syst Rev 2003; :CD003966.
  18. Kauffman CA. Candiduria. Clin Infect Dis 2005; 41 Suppl 6:S371.
  19. Hofland CA, Eron LJ, Washecka RM. Hemorrhagic adenovirus cystitis after renal transplantation. Transplant Proc 2004; 36:3025.
  20. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006; 43:331.
  21. Boeckh M, Erard V, Zerr D, Englund J. Emerging viral infections after hematopoietic cell transplantation. Pediatr Transplant 2005; 9 Suppl 7:48.
  22. Erard V, Storer B, Corey L, et al. BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors, and association with postengraftment hemorrhagic cystitis. Clin Infect Dis 2004; 39:1861.
  23. Yusuf U, Hale GA, Carr J, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006; 81:1398.
  24. Faraci M, Cuzzubbo D, Lanino E, et al. Low dosage cidofovir without probenecid as treatment for BK virus hamorrhagic cystitis after hemopoietic stem cell transplant. Pediatr Infect Dis J 2009; 28:55.
  25. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30:14.